PDCD1 and hepatocellular carcinoma: In a meta-analysis, PD-1 inhibitors (nivolumab and pembrolizumab) showed a pooled response rate of 17.3% (defined as halting of tumor progression, signs of tumor regression or tumor resolution) and overall survival of 10.4 months in patients with advanced HCC [92,93].